Device, programmed bioelectric signaling sequences and methods for the controlled expression of Klotho on demand via precise bioelectrical signaling sequences.

Leonhardt’s Launchpads, a Los Angeles, Salt Lake City and Pittsburgh based innovation and startup accelerator focused on bioelectric and biologics based organ regeneration and recovery, today announced filing of patent application for bioelectrical stimulation signaling sequences able to control the release of Klotho, a known powerful anti-aging and regeneration promoting protein, by up tp 465% increase over baseline levels.

The technology described in the patent involves precise bioelectric signaling sequences that communicate with the DNA and cell membranes within stimulated tissues to cause the cells to produce high volumes of the Klotho protein on demand.

“Our growing patent portfolio uniquely positions us at the forefront of bioelectric and stem cell biologics based organ regeneration and recovery,” said Howard J. Leonhardt, Executive Chairman and CEO, Leonhardt’s Launchpads and primary inventor of this patent.  “As leaders in this field, we continue to expand our intellectual property protections having filed over 180 new patent claims in 2018 alone and 2019 is on pace to exceed this level.”

By the terms of being part of the Leonhard’s Launchpads innovation and startup accelerator(s) all 30 startups in the accelerator have a no additional fee exclusive ownership license for their specific organ application.  Leonhardt’s Launchpads has 30 startups in these technology groups – Heart & Cardiovascular (9), Brain (1), Cosmetic & Personal Care (7), Major Organ Regeneration (12) and Cancer (1) – +

The klotho gene was identified in 1997, and encodes a protein that is produced primarily in the kidney.

Studies in mice have shown that a defect in klotho expression can lead to a syndrome resembling aging, whereas the over-expression of klotho in mice can extend life. Other studies have shown Klotho to be instrumental in improving brain cognitive function and for muscle regeneration – Such findings led scientists to name the gene after Clotho, one of the three fates in Greek mythology who spun the thread of life.

Klotho has the potential for the below listed benefits many of which are still under early stag study to be proven fully safe and effective by organ specific startups within the Leonhardt’s Launchpads innovation and startup accelerator(s) and by other researchers worldwide.

With this IP filing addition, Leonhardt’s Launchpads intellectual property portfolio now includes over 300 patented or patent pending invention claims that have been issued, filed, optioned or licensed focused one organ regeneration or recovery.

About Leonhardt’s Launchpads

Leonhardt’s Launchpads is the innovation and startup accelerator arm of Leonhardt Ventures LLC focused on bioelectric and biologics based organ regeneration and recovery.  The 2019 portfolio class has 30 startups –  The accelerator business model is to advance each organ specific innovation through first-in-man studies and then seek a strategic partner for the balance of development.


Brian Hardy
Director of Marketing
Howard J. Leonhardt
Executive Chairman & CEO –

See for more information.

Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc., 12655 W Jefferson Blvd, Los Angeles, CA 90066

Leonhardt Ventures LLC (Leonhardt Vineyards LLC DBA Leonhardt Ventures), 12760 Millennium Dr. Suite 213, Playa Vista, CA. 90094

Leonhardt’s Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84115

Leonhardt’s Launchpads Pittsburgh, Inc.,2730 Sidney Street, Suite 300m Pittsburgh, PA  15203
Warnings and Disclaimers:  Patents pending may not be issued.  Patents issued, licensed or optioned may not be maintained.  Products are early stage in development and are not yet proven safe or effective.  Company lacks sufficient resources to bring these products to commercialization.  As an investment these early stage startups have to be regarded in the highest risk category for total loss.   Forward looking statements subject to change without notice.